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2Abstract
An increasing number of manuscripts focus on the in vitro evaluation of established and novel
antitumor agents in experimental models. Whilst the design of such in vitro assays is inherently
flexible, some of these studies lack the minimum information necessary to critically evaluate their
relevance or have been carried out under unsuitable conditions. The use of appropriate and robust
methods and experimental design has important implications for generating results that are
reliable, relevant and reproducible. The Pharmacology and Molecular Mechanisms (PAMM)
group of the European Organization for research and Treatment of Cancer (EORTC) is the largest
group of academic scientists working on drug development and bundles decades of expertise in
this field. This position paper addresses all researchers with an interest in the preclinical and
cellular pharmacology of antitumour agents and aims at generating basic recommendations for
the correct use of compounds to be tested for antitumour activity by using a range of preclinical
cellular models of cancer.
3Introduction
Pharmacology is a complex multidisciplinary science that acts in concert with sister sciences
including medicinal chemistry, cell biology and physiology, medicine and pharmaceutics aiming
at identifying useful agents for disease treatment. Over the years the interest of researchers in
pharmacology, particularly those working at the preclinical level, has increased dramatically in
several fields including research against cancer. In contrast, in the past few decades researchers
at several start-up companies, in particular small biotech, and molecular biologists neglected
pharmacology in drug development and had to learn the hard way the importance of insight in
drug pharmacology. A key player in the preclinical evaluation of novel compounds and
established anticancer drugs is the use of cellular models of cancer for chemosensitivity studies.
This methodology plays a fundamental role in experimental oncology studies designed to (i)
identify new potential therapeutic agents, (ii) determine the mechanism of action (MOA) and (iii)
understand pharmacological factors that control the cellular response. The design of in vitro
tumour cell sensitivity assays is inherently simple and flexible allowing a wide range of variables
to be tested. However, this simplicity and flexibility is a “double-edged sword” and may generate
results that cannot always be accurately interpreted or easily reproduced in other laboratories.
There are many examples of cases where basic errors are made in experimental design that can
lead to misleading or even erroneous results. Furthermore, basic researchers sometimes produce
results that have little real pharmacological relevance, a consequence of using drug exposure
conditions that cannot be achieved in an organism [1-3]. In fact, there are examples from the
literature showing that different mechanisms are activated in response to drug treatment in cell
lines depending on the drug concentrations [4].
Applying proper test conditions was a joint collaborative efforts of several EORTC groups, the
Pharmacology and Molecular Mechanisms Groups (PAMM), Screening and Pharmacology
Group (SGP), New Drug Development group, the Cancer Research Campaign (CRC, now
CRUK) and the Development Therapeutics Program (DTP) of the National Cancer Institute
4(NCI) in Bethesda, MD, USA [3]. In this joint program, the so-called NCI-compounds group, a
workflow was developed to test new compounds coming from the NCI-60 cell line program of
the NCI, which was based on using proper pharmacology tools to speed up selection of potentially
active new chemical entities (NCE).The purpose of this article is to provide a series of
suggestions to ensure that scientific integrity in the conduct of in vitro chemosensitivity testing
using cellular models is maintained at the highest possible standards. This paper will effectively
be segregated into two key areas of activity (i) in vitro evaluation of anticancer drugs that are in
clinical trial or are approved for use in humans and (ii) novel compounds that are entering
preclinical testing for the first time. In addition, this manuscript will also discuss some of the
experimental models that are being used to evaluate novel and established anticancer agents.
This article presents the views of members of the EORC-PAMM group. PAMM comprises
researchers working in the fields of pharmacology, pharmacokinetics-pharmacodynamics,
pharmacogenetics-pharmacogenomics, molecular mechanisms of anticancer drug effects and
drug-related molecular pathology (http://www.eortc.org/research-field/pharmacology-
molecular-mechanisms). Our views are designed to present general criteria for preclinical studies
in which compounds with potential anticancer activity or well-known antitumour agents are
tested, whilst respecting the fact that the design of in vitro tumour cell sensitivity testing is
inherently flexible.
Design of in vitro tumor cell sensitivity assay: general principles
The basic design of in vitro tests for evaluation of tumor cell sensitivity is simple and is illustrated
in Figure 1. For adherent cell lines, cells are plated into cell culture dishes and allowed to ‘adhere
and adapt’ to the culture environment for a period of time (typically overnight or 24 hours).
Following this time period, cells are treated with the therapeutic agent in question for either (i) a
defined, short duration of exposure followed by a recovery period to allow cells to respond or (ii)
5continuous drug exposure. Following drug exposure to the test agent, cellular response can be
assessed by a variety of endpoints and these can be broadly divided into (i) clonogenic or (ii)
non-clonogenic endpoints [5-7]. Collectively, such tests can be referred to as chemosensitivity
assays, although originally the prefix “chemo” denoted chemical agents that kill microbes or
tumor cells. However, in real life, similar assays can be employed for multiple tests including
chemotherapeutic agents and radiotherapy [8]. It should be noted that in this paper chemotherapy
indicates any chemical entity foreign to the human body, including the “classical” cytotoxic
compounds (e.g. antimetabolites, nitrogen mustards, platinum compounds, tubulin antagonists,
anti-tumor antibiotics, etc), as well as novel so-called targeted drugs, such as tyrosine kinase
inhibitors (TKI), anti-angiogenesis drugs, proteasome inhibitors, etc. Each endpoint has its own
advantage and disadvantage and the choice of which one to use is generally based on individual
researcher’s preferences or specific objectives (measuring growth inhibition, cell kill, cell
survival or effects on cell population growth, for example). For suspension cultures, the
procedure is effectively the same except for the initial conditioning phase which is not mandatory.
It is important to recognize that no one single assay should be performed as a stand-alone test
from which to draw firm conclusions regarding in vitro activity against cells.
Whilst the basic design of in vitro assays is straightforward, the simplicity of this approach
obscures a multitude of factors that can influence cellular response and therefore affect the quality
and interpretation of the data obtained. A good understanding of these factors is essential to the
design of all in vitro chemosensitivity experiments, but is particularly so for those addressing
specific aspects of tumour biology and drug pharmacology. The following sections highlight
some of these issues in the context of enhancing good experimental design and avoiding poor
practice.
(i) The use of pharmacologically relevant drug concentrations for established drugs
Two key pharmacological parameters that determine cellular response are the concentration (C)
of a drug and the duration of drug exposure (T). For the majority of cytotoxic drugs, cellular
6response is usually proportional to the product of C x T with the exception of drugs that are cell
cycle phase specific, where cellular response above a certain threshold C is typically proportional
to T. In this case, extending the duration of drug exposure allows more cells to enter the sensitive
phase of the cell cycle. For drugs where good pharmacokinetics data are available (i.e., those that
have been approved for use in humans or are in advanced preclinical or early clinical trial), it is
essential that drug exposure conditions do not exceed those that are pharmacologically achievable
either in experimental murine models or humans. In general terms, therefore, the selection of
exposure parameters for use in vitro should not exceed the total plasma exposure parameters (i.e.,
area under the curve) achieved in vivo. A series of examples where the effects of using drug
exposure parameters that are not pharmacologically relevant is given below.
Concentrations of anticancer drugs in patients vary over several orders of magnitude. The choice
of adequate concentrations for in vitro experiments is critical, because killing cancer cells can be
achieved with almost every compound if the concentration is high enough. Results of preclinical
experiments using very high concentrations can be misleading and often result in false
conclusions. For example, as a result of using non-pharmacologically relevant concentrations in
such experiments, there is great confusion about the mechanism of action of anthracyclines in the
literature. As pointed out by Gerwitz [9] almost 20 years ago, many of the proposed mechanisms
for both cytotoxicity and cardiotoxicity of anthracyclines are not relevant in patients because of
exorbitant high drug concentrations used in the preclinical experiments, even exceeding the high
peak plasma concentrations achieved during short-term infusion of anthracyclines. Nevertheless,
mechanisms such as free radical formation for the anti-tumor effects of anthracyclines are still
mentioned in many textbooks. Nevertheless, mechanisms such as free radical formation for the
anti-tumor effects of anthracyclines are still mentioned in many textbooks. However, there is
uncertainty about the concentrations of anthracyclines in the tumor because a high and variable
tumor to plasma concentration ratio of doxorubicin was found in breast cancer patients [10]. In
many clinical protocols, anthracyclines are now delivered in a slow-release form (Doxil).
7As stated above, the concentrations in preclinical cell-based models should be aim to be in the
same range as the plasma concentrations achievable in vivo (Figure 2). This rule is best applicable
to haematological malignancies where the target organ is the blood itself, but it is important to
stress that for solid tumors, less is known about the C x T parameters achieved in the tumor itself.
Drug penetration barriers (consisting of influx and efflux pumps) exist for a number of anticancer
drugs and this - combined with the effect of high interstitial fluid pressure on drug penetration
into tumors - significantly modifies the C x T parameters experienced by tumor cells [11]. The
presence of a poor and inefficient vascular supply to tumors leads to the establishment of a
hypoxic microenvironment where drug delivery is significantly impaired [12]. It is technically
feasible to measure drug concentrations within a tumor but practically, this was rarely done [13],
but is getting more common, both for standard cytotoxic and novel TKI chemotherapy. In fact,
in many current clinical protocols, taking tumor biopsy specimens is mandatory and often drug
concentrations are measured. Basically, several methods are available to measure drug
concentrations in tissues and include (i) quantification in homogenized tumour tissue after
surgical excision; (ii) microdialysis by inserting a microdialysis needle placed directly into the
tumor; (iii) the use of radioactively labelled drugs (e.g., short-lived radiolabels, such as 18F); (iv),
the use of imaging techniques such as NMR and more recently mass-spectrometry based assays.
All methods have many drawbacks limiting their applicability. Therefore, the plasma
concentration has remained the golden standard because it has been established for most drugs.
It is important to acknowledge that drug concentrations based upon those achieved in the plasma
of patients are unlikely to precisely reflect the concentrations within the tumor, they either
overestimate, but often also underestimate concentrations in the tumor. Plasma concentrations
certainly do not give any information on intra-tumoral heterogeneity in drug distribution, and do
not give any information of drug sequestration, both in the tumor and in normal tissues. For
instance, a high lysosomal accumulation of sunitinib was found in tumors, due to sequestration
in lysosomes [14, 15]. Since lysosomes are less abundant in normal cells, the total cellular
8accumulation is less. Also for the classical anticancer drug 5-fluorouracil (5FU) high
concentrations (1-10 pmol/mg tumor tissue) have been reported in the tumor, even days after
administration, in contrast to the rapid plasma half-life with sub nM concentrations after 2 days
[16]. The latter is due to sequestration in polar metabolites and high-molecular weight molecules
such as RNA. It should also be recognized that many of the novel drugs (e.g., all TKI) are > 95%
protein bound [17], or due to their physico-chemical properties are trapped in tissues. In animal
models, it is usually easier to determine drug concentrations (and their retention) in the target
tissues (tumor and normal tissues) and get a better indication of the C x T. With novel tools such
as Positron Emission Tomography (PET), it is currently possible to determine the drug
concentration in several tissues [18, 19]. In several studies, serum concentrations are reported. It
should be noted that serum and plasma are often exchanged, while serum concentrations are
sometimes higher than plasma, since some drugs tend to accumulate in platelets, which are lysed
during serum preparation. A relative easy alternative for drug trapping is the measurement of
drug accumulation in red blood cells, in which drugs such as the above-mentioned sunitinib and
5FU tend to be retained longer than in plasma. Despite this, plasma concentrations after
administering therapeutic drug concentrations in humans still remain a suitable guide for the
selection of conditions for preclinical experiments to ensure the most relevant parameters to be
used in vitro.
In the absence of accurate information on the concentration of anticancer drugs in tumors,
investigators should be encouraged to study putative mechanisms of action of drugs on cultured
cells at concentrations that impact a therapeutic response (e.g., concentrations that inhibit cell
growth/survival by 50-90%, IC50 - IC90, Figure 2). IC50 values can be separated further into GI50
(test agent concentration which inhibits growth by 50%) and LC50 (“lethal concentration”,
concentration leading to death of 50% initially seeded cells – or its equivalent) response
parameters (see for detailed definitions: https://dtp.cancer.gov/discovery_development/nci-
60/methodology.htlm) . By including a simple end-point (surrogate for cell count) at the time of
9test agent addition, one can easily ascertain cell growth, test agent concentrations which inhibit
net cell growth and concentrations which cause net cell death [20, 21]. Thus, one can begin to
distinguish cytotoxic agents/agent concentrations from cytostatic ones. The response parameter
often adopted to evaluate cytostasis is TGI (concentration that totally inhibits the net cell growth
but do not kill cells) – the test agent concentration able to exert total growth inhibition. Very high
drug concentrations are unfortunately frequently used in the field of anticancer drug research.
There are numerous examples of the use of cisplatin at concentrations of 10 - 50 M (see [22]
for a discussion) and 5FU at concentrations > 500 M [23]. However, in these cases the drug
exposure should be short since for instance 5FU will reach these concentration in plasma after a
short bolus injection [24], but has a half-life of 10-15 min, while also in the FOLFOX and
FOLFIRI protocols high concentrations are reached, even for a longer period. Similarly at
standard doses of 50-100 mg/m2 cisplatin, concentrations may peak between 10-20 μM [25, 26]  
but rapidly decline (half-life < 1 hr). The average IC50 values for both these drugs are 1-10 M
in the cell lines in the NCI60 panel at 48 h exposure, but for 5FU increase to 200-400 μM and for 
cisplatin up to 200 μM at a short 1-h exposure [27]. This means that in vitro experiments with
these drugs at high concentration should be limited to a short exposure time. Microtubule
interacting agents such as paclitaxel are also occasionally used at concentrations 100-fold more
than their IC50 values [28]. The use of high drug concentrations for a prolonged period is
convenient since massive apoptosis of cultured tumor cells is generally induced within 24 hours,
a time frame that is ideal for conducting in vitro experiments. Induction of acute apoptosis by
DNA damaging drugs using high drug concentrations is the subject of a large number of studies.
A PubMed search for cisplatin, apoptosis and mechanism generates 1618 hits (June 2017). The
rate of publication of papers examining cisplatin-induced apoptosis has increased dramatically
during recent years and these studies may represent a questionable use of valuable research
resources. This problem has been pointed out by different investigators over the years [29-31],
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but the discussion has had limited impact on research directions. At even higher drug
concentration, DNA damaging drugs have been reported to result in a phenomenon referred to as
"programmed necrosis" [32]. The relevance of this death mode has been disputed [33].
The use of high drug concentrations will also accentuate alternative target effects that are unlikely
to occur at drug concentrations that can be achieved in vivo at oral administration or a slow-
release form. Cisplatin shows considerable reactivity with proteins due to its electrophilicity
toward methionine, cysteine and histidine residues; protein adducts may therefore constitute the
vast majority of cisplatin adducts in exposed cells [34, 35]. Protein adducts are expected to induce
changes in cellular homeostasis only when accumulating over a certain threshold. However,
proliferating cells are expected to be considerably more sensitive to DNA adducts than to protein
adducts. Relatively rarely will DNA adducts be catastrophic to proliferating tumor cells with
inadequate cell cycle checkpoints. Therefore, the use of extremely high cisplatin concentrations
for prolonged exposure times is likely to lead to effects that are irrelevant to the therapeutically-
relevant mechanism of action of this drug. Although such mechanisms may be of academic
interest in terms of understanding apoptosis modes, they will not be relevant to understanding
intrinsic and acquired cisplatin resistance.
(ii) The use of pharmacologically-relevant drug concentrations for novel compounds
Whilst the use of pharmacologically-relevant drug exposure parameters is easily defined for
established drugs or drugs in advanced stages of preclinical/clinical evaluation, this is clearly
difficult or even impossible for novel compounds entering the drug discovery process for the first
time. In this case, the design of the experiments should simply be determination of the IC50/GI50
values and this is typically done using continuous drug exposures (48-72 h) in the first instance.
The initial purpose is to reject compounds that do not have activity. Various selection criteria can
be applied depending on the drug discovery strategy being pursued. For example, in the case of
targeted anticancer drug development, selectivity towards cells expressing the target over those
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that do not at IC50 values that are comparable to existing therapeutics (if they exist) or compounds
with closely related mechanisms is a key decision point.
For compounds following the phenotypic drug discovery route, comparable activity to clinically
approved reference anticancer drugs (that are chemically related for example) together with
evidence of selectivity towards the tumour as opposed to non-cancer cell lines is appropriate [36,
37]. In both cases, the purpose of the in vitro chemosensitivity assay here is to generate sufficient
evidence to select a small number of compounds to progress into the next phase of testing and in
this case, the use of pharmacologically-relevant drug exposure parameters assumes less
significance.
(iii) The correct use of solvents to reconstitute pure compounds
All drugs, whether established or novel unknown compounds have to be dissolved in an
appropriate solvent and appropriately diluted for use in in vitro chemosensitivity assays. Ideally,
this should be an aqueous-based buffer but currently many novel compounds are insoluble in
aqueous buffers. Therefore, dimethylsulphoxide (DMSO) or ethanol are widely used. It has been
recently pointed out that this simple but fundamental issue in pharmacology has been neglected
when performing preclinical studies, some of which are reported in high impact peer-reviewed
journals. One can classify compounds as (i) soluble and solutions can be made in aqueous buffers;
(ii) insoluble and the drug can be solubilised in either DMSO or ethanol; (iii) insoluble and it is
recommended that the drug is prepared as a suspension. One should refrain from DMSO or
ethanol, when the drug is water-soluble. A case in question concerns cisplatin that according to
a recent paper by Hall et al. (2014) [38], has been incorrectly dissolved in DMSO providing
results that are useless (misleading and clinically irrelevent?). When dissolved in DMSO,
cisplatin generates adducts that are different from those generated upon saline dissolution or when
the drug is formulated for clinical use. Thirty years ago, Sundquist et al. reported about the
species generated when cisplatin was dissolved in DMSO [39]. This observation was
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corroborated later in a publication in which adducts structurally distinct from those generated by
correctly dissolved cisplatin are described [40]. In principle, cisplatin can be dissolved in water,
but this generates species with altered cytotoxicity. Early evidence was presented about the
possible use of “aquated” cisplatin in an attempt to increase the delivery of cisplatin to tumours
[41]. However, such an approach resulted in increased nephrotoxicity in preclinical animal
models. Thus, it appears reasonable that some discrepancies in the literature regarding platinum
drugs might be dependent on the wrong choice of solvent, suggesting the need for minimal
standard information of drug preparation for all papers in which drugs are used. Besides avoiding
inappropriate solvents, attention should be paid to drug concentrations. In several papers cisplatin
has been reported to be employed at very high concentrations that cannot be achieved in vivo.
The consequences of tumor cell exposure to low or high drug concentrations are different. For
example, the differential modulation of p53 and p73 by high and low concentrations (i.e,
pharmacologically relevant) of cisplatin has been reported in ovarian carcinoma cells [3].
An important point in making solutions in pharmacological studies is protein binding, which can
be reversible and irreversible. Sometimes protein binding is an advantage but more often a
disadvantage. Also the type of protein is important. Protein binding can be promiscuous or
specific. An excellent example which clearly affected drug development is the binding of UCN-
01 to alpha-acid glycoprotein, which is not present in culture media, while it is abundant in human
blood, where UCN-01 is almost completely inactivated. This means that in the early phase of
drug development, protein binding (human and animal albumin, alpha-acid-glycoproteine, etc)
should be quantified. On the other hand proteins seem important in the intestinal uptake of several
of the novel TKIs as was demonstrated in the CaCo-2 model (Honeywell, ADMET &
DMPK,2015). In the clinic this is seen with several drugs that show a better bioavailability when
taken with food, hence a higher protein availability.
For the clinically available antitumor agents, solvents and solubility have been optimized during
the course of preclinical and clinical development studies. Drug development efforts have
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highlighted that the effect of the solvent on the activity of the drug under study is crucial, and it
should be mandatory to provide details about the proper use of drugs in those manuscripts where
in vitro or in vivo drug activity is tested; this includes a clear description of the source of serum.
This would be helpful to improve the quality of the published literature as well to increase the
translatability of the preclinical findings.
(iv) Compound stability in vitro
A frequently underestimated aspect of pharmacology is drug stability throughout the duration of
the in vitro assay [11, 42], especially those that use continuous drug exposures [12]. The stability
of a number of cytotoxic drugs in cell culture media has been documented in the literature [42],
but is frequently ignored with potentially relevant consequences. As an example, the selection of
novel compounds for further evaluation is often based upon potency but if continuous drug
exposures are used, the most active in a series of compounds may not necessarily be the most
potent. In this hypothetical example, consider two compounds, one of which is stable in vitro
over a prolonged period (compound A) and the other is highly unstable in vitro (compound B)
with a half-life of less than one hour. Following continuous drug exposure, compound A had a
lower IC50 value and this would naturally be selected in preference to compound B, but this
conclusion is potentially misleading as compound B may actually be the most potent compound
in vitro based upon C x T parameters for the active principle. Taking compound stability into
consideration early on in the drug development process does however introduce logistic and
technical challenges, but it is important to acknowledge the potential limitations of interpreting
structure activity relationships when continuous drug exposures are used. The impact of this
problem can be reduced if other decision points such as selectivity for cancer versus non-cancer
cells are taken into account as drug instability caused by chemical breakdown should be the same
in both cell types. In addition, a simple approach to examine drug stability may be represented
by wash out experiments. Another example, constitutes the chemical instability of aza-2’-
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deoxycytidine (Decitabine). This will lead to a decreased activity of the compound; when used
small aliquots should be used, since freeze-thawing will also reduce the concentration of the
compound. Finally, it should also be stressed that breakdown of compounds in vitro does not
always lead to inactive products (Figure 3). In the case of the alkylating agent ThioTEPA for
example, it breaks down in vitro to the product TEPA which is just as active as the parent
compound [43, 44].
This example leads us to comment on the in vitro use of pro-drugs. Irinotecan or carboplatin are
often used in cellular studies and since they are pro-drugs, they are not really suitable for in vitro
experiments. A good choice would be to employ SN38 instead of irinotecan as the former is the
active metabolite of irinotecan generated upon the action of carboxylesterases, unless
investigating mechanisms of resistance to irinotecan, to which reduced levels of carboxylesterase
can be a contributory factor [45]. Furthermore, cisplatin should be used instead of carboplatin
because the two compounds form identical adducts [46], but carboplatin has a lower rate of
activation than cisplatin. With regards to aza-2’-deoxycytidine prodrugs have been developed
which bypass the intrinsic instability of the compound; an example is SGI-110.
Bio-activation is fundamentally essential for cyclophosphamide to exert its cytotoxic effects.
Cytochrome P450s, (CYPs) mainly 2B6 and 3A4, oxidize cyclophosphamide to 4-hydroxy-
cyclophosphamide (Figure 3) in the liver and this metabolite can subsequently enter cells and
decompose to phosphoramide mustard, the ultimate active agent [47]. Therefore, for investigating
the effects of cyclophosphamide in vitro, the 4-perhyxdroxy-derivatives must be used, which
spontaneously release 4-hydroxy-cyclophosphamide, which is not stable. Accordingly, for
ifosfamide, 4-perhydroxyifosfamide must be used in cell culture experiments. The anlog
mafosfamide can also be used. Many publications on cyclophosphamide do not explicitly state if
cells were incubated with the perhydroxy-derivative or cyclophosphamide itself [48].
(v) Tumor microenvironmental factors
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It is widely recognized that cell culture conditions do not mimic the complexity of tumor biology
and it is questionable as to whether or not this is the real purpose of in vitro testing. The inherently
flexible design of in vitro assays does allow the influence of tumor biology on pharmacology to
be explored systematically in a controlled manner. This is particularly true for the tumor
microenvironment. Together cellular heterogeneity, the physiological changes induced by a poor
and inefficient blood supply and elevated interstitial fluid pressure can modify various aspects of
anticancer drug pharmacology [11]. Understanding these factors is important in the design of in
vitro assays that determine the impact of the tumor microenvironment on drug activity and
cellular response. Three dimensional models may play a role in this context, but it is important
to acknowledge that two dimensional models can also provide valuable information regarding
the impact of specific microenvironmental factors on the pharmacology of anticancer drugs.
Numerous examples exist in the literature where the effects of physiological factors such as
hypoxia and acidosis on drugs have been evaluated [49, 50], but it is again important to stress
that physiologically relevant parameters should be used. For example, the extracellular pH (pHe)
in tumours is generally acidic (pHe typically ranges from 6.6 to 7.1) whereas an intracellular pH
(pHi) of 7.4 is slightly higher than that in normal cells (pHi around 7.2) [51, 52]. This shift in pH
gradients in cancer cells has profound biological and pharmacological implications [53-56] and
it is therefore essential that physiologically relevant pH conditions are employed. Studies using
more acidic pH values therefore need to be interpreted with caution.
Based upon the points raised in the above paragraphs, the following recommendations can be
made. These are as follows:
• When data are available concerning the pharmacokinetic parameters achievable in
humans or rodents, they should be used to guide the selection of concentrations to use in
the in vitro setting.
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• For novel compounds where pharmacokinetic data is not available, determination of IC50,
GI50, TGI or LC50 following continuous drug exposure is an appropriate starting point.
• For compounds that are designed to target specific biochemical pathways, the use of cell
lines where the target is well characterized or has been genetically manipulated is
appropriate.
• For compounds where the mechanism of action is not known, comparison of the activity
of the test compound against a chemically related standard agent (reference compound)
and/or comparative activity against cancer as opposed to non-cancer cells is desirable.
Often the NCI-60 cell line panel is a good starting point to find efficacy of drugs with
similar structure. Data on all drugs tested by the NCI (a few 100,000) are available or will
shortly become available. The COMPARE program often gives a suitable first insight in
mechanism of action.
• Appropriate solvents should be employed to ensure complete solubility and the
maintenance of the original chemical structure of the compound. Reporting of the
preparation of compounds for use in vitro should be clear and precise in all publications.
• Characterization of physico-chemicals properties will help to define the appropriate
solvent, but can also predict several important pharmacokinetic properties, such as drug
penetration, volume of distribution (Valko 2017, book)
• Compound stability should be taken into consideration when interpreting
chemosensitivity data and the use of additional endpoint apart from potency to select
compounds for further analysis should be considered. Freshly-prepared compound stocks
and dilutions should be used in assays but where compound supply is limited; the
preparation of stocks that are batched out and maintained at -20 °C or lower is desirable.
• Prodrugs cannot be investigated in the same way as other drugs in experiments with the
cell lines. Instead the active metabolite itself or compounds spontaneously releasing the
active metabolite must be used.
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• The endpoints used to measure cellular response can be tailored to the type or number of
compounds under development; assay and assay conditions (length of drug exposure, day
of drug addition, correction for absorbance/fluorescence/ cell count at day of drug
addition should be included. Just mentioning the commercial name of an assay is not
sufficient.
• With regards to testing the effects of specific features of the tumour microenvironment
(e.g., acidic pHe and reduced oxygenation conditions), it is important to use
physiologically relevant conditions in two-dimensional culture systems.
• A number of consideration points to optimize the experimental design are listed in Table
1.
The experimental model: general issues
Over the years there has been an increased tendency to validate the experimental models to
achieve specific objectives. The most recent example being the use of authenticated cell lines to
eliminate the possibility of cross contamination of cultures by cells such as the HeLa cell line
[57]. In contrast, evaluation of the appropriate use of antitumor compounds has been left behind
and continues to rely on researcher choice and, ultimately, on the judgement of reviewers. Such
phenomena need to be addressed, as we have long since moved from a time when
pharmacological preclinical research was conducted by a relatively small number of scientists
carrying out preclinical drug development to a scientific context where many academic and
commercial groups employ multiple pharmacological approaches designed to target biological
alterations associated with tumor pathogenesis, progression and aggressiveness.
Thus, given the heterogeneous background of researchers employing drugs in their
experiments, there are some important issues related to the experimental model that should be
taken into account. When assaying cell sensitivity to certain drugs, it may be desirable to employ
proliferating cells unless the experimental design implies that cells should not proliferate under
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the tested conditions. Cell proliferation is necessary for the cells to process the damage done to
them by drugs, although this may depend on the type of damage. When DNA damage is not
processed, the cells may turn out to be resistant to the drug (or become tolerant of drug-induced
lesions) because they do not grow or undergo only a limited number of cell divisions during the
time of the experiment. This is particularly important both for conventional anticancer agents
inhibiting DNA-related functions or cell division and for agents targeting alterations associated
with cell proliferation (e.g., EGF receptor). Low cellular proliferation rates and quiescence are
however physiologically relevant conditions within hypoxic and poorly perfused tumor
microenvironments. In the case of drug design it is desirable that new compounds target the
hypoxic tumour microenvironment and activity against slowly proliferating cells [50, 58]. An
additional caveat is represented by cells that do not proliferate rapidly, such as chronic
lymphocytic leukaemia cells. Whilst these cells replicate very slowly, they are resistant to
apoptosis as a consequence of MCL-1 expression. Agents which down-regulate MCL-1
expression (e.g., CDK9 inhibitors) impact cell survival and so measurement of apoptosis
induction becomes the critical assay endpoint [59]. Similarly, normal tissues will contain a mix
of proliferating undifferentiated cells and non-proliferating differentiated cells and therefore
studies reporting the response of non-cancer cells need to be carefully interpreted. When
interpreting observations where the IC50 of novel agents against tumor cells is compared to
normal cells, it is important to include standard agents in the study to serve as a “yardstick”
against which the activity of new agents can be measured. If the new agent performs better than
the established drug under identical experimental conditions, then there is a reasonable case for
selecting this compound for further development.
An experimental model that has attracted major attention in recent years is represented by
cancer stem cells (CSCs), a cell fraction endowed with self-renewal, differentiating and tumor
initiating properties being responsible for tumor initiation, invasive growth, metastasis and drug
resisance [60]. Although CSCs have been identified in several tumor types, the precise
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phenotypic and functional features of CSC have been well defined only in a limited number of
studies, predominantly leukemia [61, 62], so that the use of preclinical models of CSCs,
especially in vitro requires major attention (see below).
Testing cell sensitivity to drugs in in vitro assays: a variety of tests
As mentioned earlier, several end points are widely used to measure the effects of treatments on
cell lines in vitro and these can be broadly divided into clonogenic and non-clonogenic assays.
These assays do not only differ in technical nature, but also measure different cell fates. The
clonogenic assay is a classical method to measure the response of cells following drug exposure
[4]. The advantage of this assay is its ability to integrate different outcomes (apoptosis, necrosis,
mitotic catastrophe, senescence) into colony forming ability as a measure of replicative potential.
Although one is testing the ability of single cells/small cell numbers to survive brief exposure
and retain proliferative capacity, the obtained data may resemble the scenario post tumor
resection. The most commonly used type of endpoint assay however is the non-clonogenic assays
largely because these can be semi-automated [5]. These assays (described in more detail in the
next paragraph) are often referred to as determining the "cytotoxicity" of drugs which is not
entirely correct; the results reflect the difference in cell number (or surrogate for cell number)
between treated and control cultures due to effects on cell growth/proliferation and/or cell death.
Again, each endpoint has its own advantages and disadvantages and a detailed discussion of these
can be found elsewhere [RA Freshneys, book on the Culture of Animal Cells].
With regards to non-clonogenic assays, a variety of assays exist whose suitability can be tailored
to the specific objective of the study. Commonly used assays include the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] [5], its derivatives (such as the XTT,
WST), and Alamar Blue assay and the sulforhodamine B (SRB) assay [63] [6]. In the MTT/XTT
assays, the tetrazolium salts are reduced in the mitochondria of viable cells to generate formazan
products. Following solubilization of insoluble formazan products in organic solvents (MTT
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assay), the absorbance of the resulting solution can be determined and this is proportional to the
number of metabolically viable cells within the culture. Similarly, in the Alamar Blue assay,
resazurin is metabolically reduced to resorufin by viable cells [63]. As these assays provide a
measure of metabolic activity, the use of these assays to evaluate compounds that target cell
metabolism should be carefully interpreted and validated using alternative endpoints.
Furthermore, differences in the pHe of control and treated cultures led to a significant
underestimation of cell survival in cells treated with interferon using the MTT assay [64] and it
is strongly recommended that the conditioned culture medium used to culture the cells is replaced
with fresh medium immediately prior to the addition of MTT. This will apply to all assays that
depend upon metabolic read outs to measure cellular response. In the SRB assay [6], it is possible
to measure the dye binding to cellular proteins, again providing an indication of cell growth
inhibition by treatment. MTT, Alamar blue and SRB assays provide surrogate
indications/biomarkers of cell number. Many other assays are also available to assess cell
sensitivity to drugs, e.g. the CellTiterGlo luminescent cell viability assay based on quantitation
of the ATP present, a further indicator of metabolically active cells. It should be recognized that
due to their metabolic properties quite a few drugs increase the intracellular concentration of
ATP. An example is gemcitabine [65]. A simple alternative is staining with crystal violet, which
is very useful in 96-wells plate assays, as well as to count stained colonies.
In the past, the activity of many compounds has been tested by microscopically counting viable
cells using Trypan blue which is taken-up by dead cells, but excluded by intact membranes of
viable cells. As mentioned above, the clonogenic assay [5] is adopted to determine the effects of
short-term exposure on cell survival and colony formation. However, the clonogenic assay is time
consuming and less suitable to large scale screenings, but remains very useful to detected cell
death. Finally and crucially, an irrefutable measure of how a test agent may affect net cell
numbers can be determined by simply cell counting after fixed exposure periods; cell counting
21
allows direct determination of inhibition of cell growth, and when carried out with an automatic
machine can provide very reproducible results.
Testing cell sensitivity to drugs in in vitro assays: 3D models
The vast majority of studies of the response to anticancer drugs are carried out using subconfluent
monolayer cultures, conditions quite distinct from the situation in solid tumors in vivo. One
strategy to attempt to mimic in vivo conditions is to use multicellular tumour spheroids (MCTS)
[66, 67], aggregates of tumor cells formed in vitro. An alternative assay employed V-bottomed
plates, in which cells form aggregates as well and resemble 3-dimensional spheroid. The
advantage of such a system is that it can be evaluated using standard MTT and SRB assays [68].
The drug sensitivity properties resemble that of MCTS, as well as drug penetration. The
sensitivities of MCTS and V-bottom cultures to anticancer drugs is generally lower than the
sensitivities of monolayer cultures [69, 70]. This is true both for DNA damaging drugs and
microtubule interacting agents [66, 71]. The major effect of cisplatin exposure of MCTS is
senescence, whereas apoptosis is only observed in proliferating cell populations in peripheral cell
layers [71]. The general insensitivity of MCTS to cisplatin and other anticancer drugs is likely a
consequence of limited drug penetration and the presence of hypoxic, non-proliferating cell
populations. The MCTS model has been technically improved, allowing spheroids of
homogeneous size to form in multiwell plates [66], and the model is in our opinion attractive for
studies of the response of solid tumor cells to anticancer agents.
Three-dimensional models have been employed for in vitro assays using CSCs or putative
CSCs. Indeed, the setting up of reliable drug sensitivity assays is critical because the true nature
of CSCs is their tumor initiating ability that can be truly assayed only in vivo and due to the fact
that the best condition would be to use tumor specimens as a source of cells maintaining stem-
like features. However, isolation of CSCs from clinical specimens is not always successful [72].
In principle, once the stemness of a peculiar model has been established, drug sensitivity can be
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assessed by testing drug effects on spheres [73]. In fact, CSCs are capable of growing
independently of anchorage (i.e. as spheres) in serum-free medium added with growth factors. In
this context, there are several caveats to consider. For example, growth factors activate survival
pathways that may influence response to drugs of different classes. Therefore, it remains difficult
to standardize cell sensitivity assays of CSCs.
Alternatively, organoid cultures represent an appealing experimental model for testing antitumor
agents because of the potential to model cancer in vitro, somehow respecting the complexity of
the disease and recapitulating the three-dimensional tumor organization [74].
3D models: Drug penetration
A major limiting factor in the effectiveness of chemotherapy is poor and inadequate extravascular
penetration of anticancer drugs [11]. Whilst drug penetration barriers have been identified using
drugs that are naturally fluorescent or radioactively labelled [11], the development of the
multicell layer cell culture models have enabled the kinetics of drug penetration to be determined
using routine analytical techniques [75]. Whilst good penetration of drugs into avascular regions
of tumors is desirable in all cases, it is an absolute requirement for drugs that are designed to
target the hypoxic fraction of tumors [50, 58, 76]. The kinetics of drug penetration has been
combined with mathematical modelling to generate in silico models that can help drug
development pathways in terms of selecting and designing compounds that can penetrate into
such regions of tumors [77, 78].
Testing of drug combinations
A common goal of preclinical researchers is to discover synergistic interactions between drugs.
The postulated rationale for the use of combination treatment regimens includes: reduction of
single agent doses in order to minimize adverse systemic toxicity and spare normal tissues [79,
80]; target more tumor cells, bearing in mind the heterogeneous nature of malignant disease;
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avoid or delay emergence of acquired drug resistance. However, in combination therapies it is
often neglected that a reduction of the dose of a drug invariably results in a decreased efficacy,
while the efficacy of a combination is often not compared to the efficacy of a single drug at its
maximal tolerated dose (MTD). This means that a combination does not make sense when its
efficacy is similar or less than that of each single drug at its MTD. Moreover, in a combination
of the drugs may not only enhance the antitumor effect, but also the toxicity. Therefore toxicity
of the combination should also be compared to that of the single drug at its MTD.
Nevertheless there are many combinations, which fullfill these criteria and have successfully been
translated from the cell culture to the mouse model to the patients and clearly improved the
efficacy compared to the single drugs [81]. Many approaches have been described over the years
aimed at identification of synergistic interactions, including the simple Bliss independence
method re-proposed by Kern in 1989 [82], the Loewe isobologram, Webb fractional product
concept of synergy and the median drug effect methodology developed by Chou and Talalay [79,
83]. In this method, a combination index (CI) is calculated at various fraction affected (FA) in
which a FA of 0 is no effect and a FA of 1 is complete growth inhibition. The Chou and Talalay
method is widely used for determination of synergy, additivity or antagonism between drugs in
combination. However, the method is often used incorrectly; e.g. it does not make sense to
demonstrate synergism at a total of 25% growth inhibition level (FA = 0.25) , since that means
that the tumor still grows at a 75% rate compared to untreated; even an increase to 50% inhibition
(FA=0.5) still means 50% growth of a tumor. The normal application of the method is limited to
95% growth inhibition (FA=0.95) and cell kill cannot be included in the formula, since it does
not allow negative values nor values of FA>1.0. It is recommended that in the application of this
method only FA values between 0.5 and 0.95 are included [80], while an adaptation of the
methods also allows evaluation of cell kill.
Unfortunately, there are still papers published where the improved effect of the combination in
vitro has been assessed in the absence of adequate mathematical analysis, or an incorrect use of
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mathematics. Although discussion of the best method to evaluate drug interaction is out of the
scope of this manuscript, we would like to highlight the importance of a correct application of
one of the available methods for assessing synergism in in vitro tests for drug interactions
(outlined above). With few exceptions, such studies should not rely merely on statistical analyses
by (for example) the Student’s t (or similar) tests.
Concluding remarks
The current scenario of pharmacological science implies both pharma-driven efforts and
academic contribution to innovate drug development and to optimize therapeutic approaches
toward the path of personalized medicine. The translatability of preclinical research on antitumor
agents is only in part successful for several reasons, including issues related to changes in
strategies in academic anticancer drug discovery [3] and experimental models and experimental
design applied in the preclinical setting [84]. A pertinent example is provided by EGFR inhibitors
finally discovered to act on the mutant receptor [85]. An improvement in terms of preclinical
research translatability may be provided also by the application of more stringent criteria and
transparency throughout preclinical phases of testing.
A recent publication authored by Alan Eastman has highlighted the importance of the appropriate
use of cytotoxicity assays and combination models to improve anticancer drug development [86].
The author highlights the high failure rate of anticancer agents considering possible drug or
experimental model-related reasons. The latter issue is still forefront; also taking into account
that murine models only in part mirror the complexity of human tumors.
There is an urgent need to improve the quality of preclinical results obtained with new compounds
and with clinically available agents. Researchers in the field of pharmacology generally know by
virtue of their training about the relevance of solvents, concentrations, use of drugs versus pro-
drugs, inclusion of pertinent controls and stringent, reproducible assay conditions in cellular
pharmacology studies. However, researchers in the field of molecular biology often lack this
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background. In this context, attention should be paid (in addition to cell culture conditions) to
cell behavior and to reagents used for cell culture [87]. In fact, the most widely used cell culture
supplement (fetal bovine serum) is very complex, its bioactive compounds vary between batches
and may affect the outcome of cell sensitivity tests. However, it should not be difficult for
beginners to consider all the possible sources of variability and to set up antitumor pharmacology
experiments properly, given that all the scientific community can access a lot of information
about compound solubility, stability and sensitivity assays through multiple web-available
sources. We hope that the issues raised herein offer the opportunity to reflect upon relevant points
and act as “pocket” guidelines to motivate good practise in design of pharmacology experiments,
and to include in their articles the necessary information for the tested agents.
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Table 1. Suggestions in the design of preclinical in vitro testing experiments
Choice of the compound concentration
After testing a wide range of concentrations, am I carrying out the relevant experiments using
clinically meaningful concentrations?
Choice of the exposure and recovery time
Do I allow the cells to proliferate long enough to assess the treatment outcome?
Did I consider cell doubling time?
Did I match the drug exposure time to the retention of the drug in vivo, a high concentration only
for a short time?
Choice of solvent
Is the compound water or fat soluble (lipid and non polar solvents)?
Is the solvent (e.g. DMSO or ethanol) used at concentrations that are non toxic for the cells?
Is the dissolved compound stable so that it can be stocked at low temperature (-20°C; -80°C)?
Does the compound show protein binding; is that reversible?
Choice of the compound
Is the compound stable?
Is the compound a pro-drug?
If I am using a pro-drug in vitro, can I substitute it with the active metabolite?
Choice of cell sensitivity assay
Does the endpoint of the assay addresses the experimental question correctly?
Does the method recommend and allow to correct for the number of cells at the time of drug
addition?
Choice of experimental model
Does the experimental model express the target of interest?
34
Legends to figures
Figure 1. Basic experimental design for the conduct of in vitro chemosensitivity assays using
adherent cell lines. The central bar is a time line and the key steps are placed on this time line.
The procedures for conducting continuous and timed drug exposures are presented in panels A
and B respectively. The procedures for suspension cultures are the same with the exception of
the conditioning period in culture plates which isn’t required. The endpoint here refers to non-
clonogenic assays as clonogenic assays usually require longer times for colony formation to
occur. Readings should be performed at the time of drug addition and at the endpoint.
Intermediate time-points can be very informative since they give insight in the dynamics of drug
response. With several of the novel assays, that do not require addition of a dye, it is possible to
do these measurements.
Figure 2. Criteria for selecting drug concentrations and solvent choice for in vitro cell sensitivity
assays. The two main conditions, i.e. use of established drugs or novel compounds are
represented, besides a summary of the possible solvents.
Figure 3. Structure of selected drugs, prodrugs and their active metabolites. The alkylating
agent ThioTEPA breaks down in vitro to TEPA which is equally active as the original compound.
Cisplatin and carboplatin form identical DNA adducts. SN-38 is the active metabolite formed
from irinotecan by carboxylesterases. Cyclophosphamide is converted to 4-
hydroxycyclophosphamide by P450.
